Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Solar, Inc. (FSLR) vs Heron Therapeutics Inc (HRTX) Price & Performance

First Solar, Inc.Trade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

First Solar, Inc. vs Heron Therapeutics Inc — how do they compare? First Solar, Inc. trades at $226.56 (market cap $25.89B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: First Solar, Inc. is far larger — about 421.2× Heron Therapeutics Inc's market cap, and First Solar, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

FSLRHRTX
Market Cap
$25.89B$61.47M
Sector
TechnologyHealth
52-Week High
$318.30$1.49
52-Week Low
$180.05$0.32
Enterprise Value
$24.36B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Solar, Inc.

First Solar (FSLR) trades at $227.36, down 5.0% on the day, as the stock faces headwinds from multiple class action lawsuits alleging securities fraud during the February 2025-2026 period. Despite the legal overhang, the company maintains strong fundamentals with revenue growing from $2.6B in 2022 to $5.2B in 2025 and net income reaching $1.53B. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $230 and resistance at $245. Recent analyst upgrades provide optimism, with Baird raising its price target to $318 on August 11, 2026.

The investment outlook remains cautiously optimistic given FSLR's robust profitability metrics (32.5% net margin, 18.5% ROE) and analyst consensus price target of $282 representing 24% upside potential. However, significant legal risks from ongoing securities litigation and potential regulatory headwinds from solar trade policies create near-term uncertainty. Long-term growth prospects in renewable energy remain intact, but investors should weigh legal resolution timelines against fundamental strength.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Solar, Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.

Read more on FSLR

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX